Introduction
============

Duodenal-type follicular lymphoma (FL) is an extremely rare variant of FL among primary non-Hodgkin lymphomas of the gastrointestinal tract \[[@b1-crt-2018-190],[@b2-crt-2018-190]\]. This disease entity was previously included in primary intestinal follicular lymphoma. However, it was prosed as a new subtype of FL in the World Health Organization (WHO) classification due to its distinctive and clinical features \[[@b3-crt-2018-190]\]. Although FL predominantly occurs as a nodal disorder and is a more common subtype of lymphoma in Western countries than in Asian countries, duodenal-type FL has been reported more frequently in Asian countries, especially in Japan \[[@b4-crt-2018-190],[@b5-crt-2018-190]\]. Basically, it shares similar pathology findings with nodal FL including morphology and positivity for CD10 and Bcl-6 immunohistochemistry \[[@b6-crt-2018-190]\]. However, its clinical features are closer to mucosa-associated lymphoid tissue (MALT) lymphoma rather than nodal FL because it is usually confined to the duodenum as a localized disease \[[@b5-crt-2018-190]\]. Indeed, a comprehensive gene expression analysis showed that gene expression profiles of duodenal-type FL were more closely related with MALT lymphoma than nodal FL \[[@b7-crt-2018-190]\]. Accordingly, radiation therapy (RT) is the first consideration for newly diagnosed duodenal-type FL in many institutes similar to limited stage disease of nodal FL where irradiation as preferred treatment option for localized disease \[[@b8-crt-2018-190],[@b9-crt-2018-190]\]. A recent report of single center experience with 21 cases of duodenal-type FL also demonstrated that RT could be an effective initial treatment for this disease entity \[[@b10-crt-2018-190]\]. Nevertheless, there is still no consensus on the initial treatment for duodenal-type FL or the optimal timing and target volume of RT. Because of its low incidence, few data are available on the treatment outcome of patients who were treated with RT. Furthermore, the clinical features and endoscopic findings of patients with duodenal-type FL are still not familiar to most physicians. Therefore, in this study, we analyzed patients with duodenal-type FL who were consecutively treated with RT and report their clinical features including endoscopic findings and the treatment outcome.

Materials and Methods
=====================

1. Patients
-----------

A total of 20 patients were diagnosed with duodenal-type FL at the Samsung Medical Center between 2008 and 2017. Endoscopic biopsy was performed in all patients and they were diagnosed by an expert pathologist for lymphoma (Y.H.K). Staging work-up was done including physical examination, laboratory studies, computed tomography (CT) scans of thorax and abdomen, 2-deoxy-2-fluorine-18-fluoro-D-glucose positron emission tomography integrated with CT (^18^F-FDG PET/CT) scan, and bilateral bone marrow biopsy and aspiration. Colonoscopy was done at the time of diagnosis; however, double-balloon enteroscopy or capsule endoscopy was not performed. After staging work-up, patients received involved-site RT with curative intent. Each patient fasted for at least 8 hours before the simulation. The planning CT scan was acquired in a supine position during free breathing. For all patients, a four-dimensional CT (4D CT) was acquired at our institution. In 4D CT, the movement of the third part of the duodenum craniocaudally ranged from 0.75 to 2 cm. The clinical target volume (CTV) included the whole duodenum. The internal target volume (ITV) for the CTV was delineated. The planning target volume (PTV) was defined with a margin of 1-1.5 cm to the CTV or ITV. A three-dimensional conformal RT technique was used in 13 patients and intensity-modulated RT (IMRT) in seven patients. One-arc volumetric modulated arc therapy technique was used for IMRT planning. Basically, the goal of planning the radiation field was that 95% of PTV should be covered by 99% of prescribed dose. Furthermore, a volume greater than one cubic centimeter does not receive more than 107% of the prescribed dose. Before 2013, RT was delivered with 30-36 Gy. Thereafter, RT was delivered with 24 Gy in 12 fractions. Chemotherapy was administered as an initial regimen for one patient. After the completion of RT, followup endoscopic examination was carried out to confirm complete response (CR). During follow-up, endoscopy and/or surveillance CT scan were regularly performed to monitor the occurrence of local and systemic relapse. We performed a follow-up evaluation every 3 to 4 months during the first year. After that, the follow-up interval was 6 months to 1 year.

2. Study methods
----------------

We retrospectively reviewed the medical records of all patients with duodenal-type FL to analyze their clinical features and treatment outcome. The pathology report, including the WHO grade of FL, was reviewed to confirm the diagnosis of FL. The staging was based on the Lugano classification for gastrointestinal tract lymphoma, and the prognostic group was determined by the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) \[[@b11-crt-2018-190]\]. We also reviewed endoscopic findings of all patients to categorize the duodenal involvement pattern of FL. Information concerning RT-related toxicities, relapses, and outcomes was collected in a review of medical records. The last survival status was updated at the time of analysis in March 2018, and overall and progression-free survival outcomes were analyzed.

3. Ethical statement
--------------------

All aspects of the study were approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2017-08-002), and informed consent was exempted due to the retrospective nature of this study.

Results
=======

1. Characteristics of patients at diagnosis
-------------------------------------------

The median age of patients at diagnosis was 52 years (range, 26 to 66 years); 16 patients were ≤ 60 years ([Table 1](#t1-crt-2018-190){ref-type="table"}). Females were predominant (n=14, 70%), and the majority of patients (n=18, 90%) had stage I disease confined to the duodenum. Only one patient had evidence of bone marrow involvement; however, only 5% of cells were positively stained for CD20 and morphologically consistent with lymphoma in the tissue sample of bone marrow biopsy. This case with bone marrow involvement had grade 1 disease, and the flow cytometry of bone marrow aspirates did not show any evidence of lymphoma. As we could not determine its clinical significance, we treated the patient like other patients with stage I. Most patients (n=15, 75%) were asymptomatic at diagnosis and were incidentally diagnosed as part of a regular preventive medical examination. Only three patients complained of mild abdominal discomfort and dyspepsia at diagnosis. The elevation of serum lactate dehydrogenase (LDH) was observed in only one case; thus, all patients were scored as low risk on the IPI. FLIPI scoring also showed that all patients were low risk (0 to 1) ([Table 1](#t1-crt-2018-190){ref-type="table"}). Nineteen patients were grade 1 in the WHO histological classification (95%), and the remaining patient was diagnosed as grade 3A. The staging work-up with CT scan and PET/CT showed no evidence of wall thickening or distant metastasis involving other organs such as gastrointestinal tract, liver, and spleen. The ^18^F-FDG avid lesion of the primary site was found only in two patients (patient 8 and 12) with \> 5.0 of standardized uptake value (Deauville score 4) ([Fig. 1](#f1-crt-2018-190){ref-type="fig"}). Thus, most patients had localized disease although the whole intestine was not evaluated by capsule endoscopy or double-balloon enteroscopy.

2. Endoscopic finding of the primary lesion
-------------------------------------------

Primary lesions were confined to the duodenum in all cases; however, their gross appearance was variable from multiple polypoid to multiple granular lesions. The size of polypoid lesions was also variable from small nodules to 2 cm-sized polyps, and the color and texture of all lesions were mainly a whitish granular pattern ([Fig. 2](#f2-crt-2018-190){ref-type="fig"}). Thus, according to the endoscopic findings, the pattern of involvement was classified as follows: diffuse nodular (n=8), whitish granular (n=8), and mixed pattern (n=4) ([Fig. 2](#f2-crt-2018-190){ref-type="fig"}). The site most commonly involved was the second portion of the duodenum (n=19); the second and third portions of the duodenum were involved in one patient.

3. Treatment and survival outcome
---------------------------------

Among 20 patients, 19 patients received initially RT after diagnosis. One patient who was diagnosed in 2008 received 6 cycles of CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy after diagnosis. However, the followup endoscopy and biopsy demonstrated disease progression 1.6 years after the completion of chemotherapy. Thus, he received RT as a salvage treatment. As a result, seventeen patients received RT with 24 Gy in 12 fractions, and three patients received 30-36 Gy with conventional fractionations. RT response was evaluated with endoscopy, and CR was achieved in 19 cases. We performed endoscopic biopsy to confirm pathological CR, and pathological examination of biopsy samples showed no evidence of disease. However, one patient (patient No. 6) ([Fig. 3A](#f3-crt-2018-190){ref-type="fig"}) showed partial response on endoscopy at the 3-month follow-up after RT ([Fig. 3B](#f3-crt-2018-190){ref-type="fig"}). Biopsy specimen also revealed residual tumor. This lesion was still persistent on re-biopsy at 6 and 9 months after RT ([Fig. 3C](#f3-crt-2018-190){ref-type="fig"} and [D](#f3-crt-2018-190){ref-type="fig"}). Finally, irradiation of 20 Gy was delivered to this patient, again. After that, the patient achieved CR and maintained the response. Another patient (patient No. 14) ([Fig. 3E](#f3-crt-2018-190){ref-type="fig"}) achieved CR in duodenal lesion showed CR ([Fig. 3E](#f3-crt-2018-190){ref-type="fig"}), but the colonoscopy revealed nodular lesions in the terminal ileum ([Fig. 3G](#f3-crt-2018-190){ref-type="fig"} and [H](#f3-crt-2018-190){ref-type="fig"}). The biopsy showed the presence of FL in the terminal ileum, thus, six cycles of rituximab--cyclophospha-mide, vincristine, and prednisone (R-CVP) were performed. CR was achieved after chemotherapy, and the patient was alive without evidence of disease ([Fig. 3I](#f3-crt-2018-190){ref-type="fig"}). The patient (patient No. 9) ([Figs. 1C](#f1-crt-2018-190){ref-type="fig"}, [D](#f1-crt-2018-190){ref-type="fig"} and [2C](#f2-crt-2018-190){ref-type="fig"}, [D](#f2-crt-2018-190){ref-type="fig"}) with stage IV disease (bone marrow involvement) also achieved CR after RT and maintained CR at the time of analysis without evidence of systemic progression. We have only one patient who had initially serum LDH elevation (602 IU/L; normal range, 240 to 480 IU/L) ([Table 1](#t1-crt-2018-190){ref-type="table"}). Three months after the completion of RT in this patient, the serum level of LDH was recovered to 305 IU/L. At the time of analysis, only two patients who were initially treated with RT experienced disease progression or relapse after the completion of RT ([S1 Fig.](#SD1-crt-2018-190){ref-type="supplementary-material"}). All acute toxicities related with RT were grade 1 and most of these patients experienced mild nausea (n=15). Other symptoms were abdominal pain or discomfort (n=7), dyspepsia (n=3), fatigue (n=3), anorexia (n=2), vomiting (n=2), and diarrhea (n=2). No grade 2 or greater acute toxicities were observed during RT and over the follow-up period. The toxicities of patients receiving second RT and R-CVP chemotherapy were not different from that of remaining patients receiving RT alone. The median follow-up time was 20 months (range, 11 to 110 months) because 13 patients (65%) were diagnosed between 2015 and 2017. At the time of analysis, all patients survived without any evidence of disease relapse and late toxicities related with RT.

Discussion
==========

Duodenal-type FL is known as having a different pathogenesis to that of nodal FL. Thus, the biology of duodenaltype FL may be different although the initial event with the occurrence of t(14;18)(q32;21) in B cells of the duodenal mucosa was the same as that of nodal FL. Additional major oncogenic events might be absent in duodenal-type FL, and this might be related with the rarity of systemic dissemination and large cell transformation whereas most nodal FL can acquire additional genetic changes resulting in widespread disease \[[@b12-crt-2018-190],[@b13-crt-2018-190]\]. The expression of a mucosal adhesion molecule, α4β7, was also demonstrated in duodenal-type FL, but not in nodal FL, which may increase the likelihood of localized disease in duodenal-type FL \[[@b14-crt-2018-190]\]. Similarly, duodenal-type FL and MALT lymphoma have strong expression of macrophage inflammatory protein-3α (CCL20) and its receptor, CCR6 \[[@b7-crt-2018-190]\]. The chronic inflammatory reaction induced by CCL20 in the gastrointestinal tract might influence the occurrence of duodenal-type FL and MALT lymphoma.

The comparison of our study with previous Japanese and European retrospective cohorts showed several points of difference \[[@b10-crt-2018-190],[@b13-crt-2018-190]\]. First, the median age of our study was younger. The reason for our younger sample might be influenced by the early detection of duodenal lesions by endoscopy in Korea because most Koreans can receive endoscopic examinations under the government-sponsored annual health examination. However, given that Japanese people also have easy access to endoscopy through the screening program of their national health insurance system \[[@b15-crt-2018-190]\], the earlier age of diagnosis in Korea needs to be investigated further. Second, the predominance of female patients was noted in ours and the Japanese study unlike the European study \[[@b10-crt-2018-190],[@b13-crt-2018-190]\]. This point should be clarified in future studies by comparing Western and Asian patients with duodenal-type FL. Third, the number of patients with abdominal pain was higher in the European study than in ours and the Japanese study, perhaps because most Asian cases were found as part of a regular health examination in the asymptomatic state. The histological grade and the distribution of stage were similar between the three studies, and most patients' risk on the IPI and FLIPI were scored as low ([Table 2](#t2-crt-2018-190){ref-type="table"}). When we analyzed the endoscopic findings of duodenal lesions, the main appearance was nodular or fine granular patterns consistent with previously observed findings \[[@b16-crt-2018-190]\].

The response to RT was excellent in the Japanese, European and our studies, and the response was maintained at the time of analysis. Thus, RT could be an effective initial treatment although there is no consensus on the best treatment option for duodenal-type FL. Considering that the diagnosis of lymphoma itself might give psychosocial stress to patients, RT could be the preferred option to a watch-andwait strategy. However, the RT dose was variable between the studies ([Table 2](#t2-crt-2018-190){ref-type="table"}). Since a randomized study comparing a standard dose (40-45 Gy in 20-23 fractions) with a low dose (24 Gy in 12 fractions) in indolent lymphomas showed no difference of response rate and survival \[[@b17-crt-2018-190]\], an RT dose of 24 Gy has been recommended for indolent lymphoma \[[@b18-crt-2018-190]\]. However, there is still insufficient data to confirm the efficacy of low-dose RT in duodenal-type FL. Our results with an RT dose of 24 Gy showed excellent outcomes comparable to that of Japanese and European studies using an RT dose of 30 Gy or greater \[[@b10-crt-2018-190],[@b13-crt-2018-190]\]. Although the optimal target volume of RT is also uncertain, the International Lymphoma Radiation Oncology Group guideline recommends including the entire duodenum \[[@b18-crt-2018-190]\]. This is reasonable considering the very favorable clinical course of duodenal-type FL and increasing toxicity of a larger RT field. However, the need to extend the RT to the whole intestine still exists because duodenal-type FL often has multifocal lesions in the intestine \[[@b7-crt-2018-190]\].

Due to the nature of retrospective study, our study has a number of limitations. First, we did not perform a full evaluation for involvement of the small intestine. Thus, our staging work-up might have insufficiently reflected the exact amount of disease. However, considering the indolent nature of duodenal-type FL, it is not clear whether evaluation of the whole intestine would be beneficial for patients. Second, the median follow-up duration (20 months) was not sufficiently long to provide clear information about the occurrence of systemic relapse and transformation to large cell lymphoma. However, a previous study with a median follow-up of 77 months found no cases of systemic relapse or transformation among patients receiving RT \[[@b13-crt-2018-190]\]. Therefore, the risk of systemic progression or transformation might be minimal in patients with duodenal-type FL who were treated with RT. In addition, there is a lack of data about RT-induced longterm toxicities due to a short duration of follow-up.

In summary, duodenal-type FL had endoscopically unique findings and indolent clinical features. RT alone could effectively control duodenal lesion, although a further study with longer follow-up duration is warranted to confirm our findings.
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![Initial computed tomography (CT) and positron emission tomography (PET)/CT scan imaging. (A, C, E, G, I, K) Most patients do not have severe wall thickening in the CT scan. (B, D, F, H) 2-Deoxy-2-fluorine-18-fluoro-D-glucose (FDG) uptake is not increased at the primary tumor site in the PET/CT. (J, L) Only two patients show increased FDG uptake (yellow circle).](crt-2018-190f1){#f1-crt-2018-190}

![Endoscopic findings of duodenal-type follicular lymphoma consist of diffuse nodular (A, E, I) and a whitish granular pattern (C, G, K). These lesions disappear after radiation therapy (RT) (B, D, F, H, J, L).](crt-2018-190f2){#f2-crt-2018-190}

![(A) Initial lesions of patient No. 6. (B) Improved lesions on endoscopy at 3-month follow-up after radiation therapy. Biopsy also reveals residual tumor. (C) Endoscopic examination at 6-month follow-up shows no significant change. (D) At 9-month follow-up, the lesion progresses, and re-biopsy shows persistent disease. Finally, re-irradiation of 20 Gy is carried out on this patient. (E) Initial lesions of patient No. 14. (F) Complete response on endoscopy at 3-month follow-up after radiation therapy. (G) Relapse outside the radiation field. Colonoscopy reveals nodular lesions in the terminal ileum. Biopsy proves the presence of follicular lymphoma. (H) Follow-up colonoscopy shows progressive disease. (I) After six cycles of rituximab--cyclophosphamide, vincristine, and prednisone, complete response is achieved, and the patient is alive without evidence of disease.](crt-2018-190f3){#f3-crt-2018-190}

###### 

Patient characteristics at diagnosis

  Characteristic                No. (%)
  ----------------------------- ------------
  **Age (yr)**                  
   ≤ 60                         16 (80)
   \> 60                        4 (20)
  **Sex**                       
   Male                         6 (30)
   Female                       14 (70)
  **Performance status**        
   ECOG 0/1                     20 (100)
   ECOG ≥ 2                     0
  **Abdominal pain**            
   Absence                      17 (85)
   Presence                     3 (15)
  **Lugano stage**              
   I                            18 (90)
   II1                          1 (5)
   II2                          0
   IV                           1 (5)
  **Hemoglobin (g/dL)**         
   ≥ 12                         18 (90)
   \< 12                        2 (10)
  **Serum LDH**                 
   Normal                       19 (95)
   Elevated                     1 (5)
  **Bone marrow involvement**   
   Absence                      19 (95)
   Presence                     1 (5)
  **WHO histological grade**    
   1                            19 (95)
   2                            0
   3A                           1 (5)
   3B                           0
  **IPI risk (score)**          
   Low (0/1)                    15/5 (100)
  **FLIPI risk (score)**        
   Low (0/1)                    13/7 (100)

ECOG, Eastern Cooperative Oncology Group; LDH, Lactate dehydrogenase; WHO, World Health Organization; IPI, International Prognostic Index; FLIPI, Follicular Lymphoma International Prognostic Index.

###### 

Comparison of our study results with previous studies

  Characteristic                                                 Our study (n=20)   Harada et al. \[10\] (n=21)   Schmatz et al. \[13\] (n=63)
  -------------------------------------------------------------- ------------------ ----------------------------- ------------------------------
  **Country**                                                    Korea              Japan                         Germany/Austria
  **Period**                                                     2008-2017          2005-2013                     1997-2008
  **Follow-up (mo)**                                             20.0               43.2                          77.0
  **Age (yr)**                                                   52 (26-66)         62 (46-79)                    65 (32-83)
  **Sex**                                                                                                         
   Male                                                          6 (30)             6 (29)                        31 (49)
   Female                                                        14 (70)            15 (71)                       32 (51)
  **Abdominal pain**                                                                                              
   Absent                                                        17 (85)            19 (90)                       22 (35)
   Present                                                       3 (15)             2 (10)                        41 (65)
  **Lugano stage**                                                                                                
   I                                                             18 (90)            20 (95)                       63 (100)
   II1/II2/IV                                                    1 (5)/0/1 (5)      1 (5)/0/0                     
  **Histological grade**                                                                                          
   1                                                             19 (95)            17 (81)                       63 (100)
   2                                                             0                  4 (19)                        
   3A/3B                                                         1 (5)/0                                          
  **IPI risk**                                                                                                    
   Low                                                           20 (100)           21 (100)                      Not reported
  **FLIPI risk**                                                                                                  
   Low                                                           20 (100)           19 (90)                       62 (98)
   Intermediate                                                  0                  2 (10)                        1 (2)
  **Duodenal location**                                                                                           
   2nd portion                                                   19 (95)            15                            Not specified
   3rd portion                                                   0                  3                             
   2nd and 3rd portions                                          1 (5)              2                             
   2nd and 4th portions                                          0                  1                             
  **PET/CT**                                                                                                      
   Positive                                                      2                  7                             Not reported
   Negative                                                      17                 12                            
  **Initial treatment**                                                                                           
   Radiation therapy                                             19 (95)            21 (100)                      19 (30)
   Watch and wait                                                                                                 24 (38)
   Rituximab                                                                                                      5 (8)
   Chemotherapy^[a)](#tfn1-crt-2018-190){ref-type="table-fn"}^   1 (5)                                            8 (13)
  **Radiation therapy**                                                                                           
   Dose (Gy)                                                     24-36              30-36                         30-45
   CR/PR                                                         19/1               Not reported                  19/0
   Local progression                                             1                  0                             
   Systemic progression                                          1                  4                             
   Death                                                         0                  0                             0

Values are presented as median (range) or number (%). IPI, International Prognostic Index; FLIPI, Follicular Lymphoma International Prognostic Index; PET/CT, positron emission tomography/computed tomography; CR, complete response; PR, partial response.

Some patients also received radiation therapy after chemotherapy.
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